Tricking the balance: NK cells in anti-cancer immunity

Immunobiology

Volumn 222, Issue 1, 2017, Pages 11-20

  Pahl, Jens ^a   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer; Immunotherapy; Innate immunity; NK cell

Indexed keywords

HLA E ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; MYELOID DIFFERENTIATION FACTOR 88; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZBTB32; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOKINE; HLA ANTIGEN CLASS 1;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER INCIDENCE; CELL DESTRUCTION; CELL EXPANSION; CYTOKINE PRODUCTION; HUMAN; IMMUNOLOGICAL MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84957729571     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.07.012     Document Type: Review

References (166)

1. Abes, R., Gelize, E., Fridman, W.H., Teillaud, J.L., Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116 (2010), 926–934.
2. Alvarez-Breckenridge, C.A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., Fernandez, S.A., Kaur, B., Lawler, S.E., Vivier, E., Mandelboim, O., Moretta, A., Caligiuri, M.A., Chiocca, E.A., NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18 (2012), 1827–1834.
3. Anfossi, N., Andre, P., Guia, S., Falk, C.S., Roetynck, S., Stewart, C.A., Breso, V., Frassati, C., Reviron, D., Middleton, D., Romagne, F., Ugolini, S., Vivier, E., Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342.
4. Ardolino, M., Azimi, C.S., Iannello, A., Trevino, T.N., Horan, L., Zhang, L., Deng, W., Ring, A.M., Fischer, S., Garcia, K.C., Raulet, D.H., Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124 (2014), 4781–4794.
5. Arnon, T.I., Achdout, H., Lieberman, N., Gazit, R., Gonen-Gross, T., Katz, G., Bar-Ilan, A., Bloushtain, N., Lev, M., Joseph, A., Kedar, E., Porgador, A., Mandelboim, O., The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 103 (2004), 664–672.
6. Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V., Fermeaux, V., Bertheau, P., Garnier, J., Jeannin, J.F., Coudert, B., Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 94 (2006), 259–267.
7. Artis, D., Spits, H., The biology of innate lymphoid cells. Nature 517 (2015), 293–301.
8. Bacon, L., Eagle, R.A., Meyer, M., Easom, N., Young, N.T., Trowsdale, J., Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J. Immunol. 173 (2004), 1078–1084.
9. Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M.Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S.P., Bleackley, R.C., Goping, I.S., Chouaib, S., Janji, B., Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 17450–17455.
10. Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., Moretta, L., Mingari, M.C., Vitale, M., Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 20847–20852.
11. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999), 727–729.
12. Baychelier, F., Sennepin, A., Ermonval, M., Dorgham, K., Debre, P., Vieillard, V., Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 122 (2013), 2935–2942.
13. Beaulieu, A.M., Zawislak, C.L., Nakayama, T., Sun, J.C., The transcription factor Zbtb32 controls the proliferative burst of virus-specific natural killer cells responding to infection. Nat. Immunol. 15 (2014), 546–553.
14. Beziat, V., Liu, L.L., Malmberg, J.A., Ivarsson, M.A., Sohlberg, E., Bjorklund, A.T., Retiere, C., Sverremark-Ekstrom, E., Traherne, J., Ljungman, P., Schaffer, M., Price, D.A., Trowsdale, J., Michaelsson, J., Ljunggren, H.G., Malmberg, K.J., NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121 (2013), 2678–2688.
15. Bibeau, F., Lopez-Crapez, E., Di, F.F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frebourg, T., Michel, P., Sabourin, J.C., Boissiere-Michot, F., Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27 (2009), 1122–1129.
16. Bjorkstrom, N.K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M.A., Bjorklund, A.T., Flodstrom-Tullberg, M., Michaelsson, J., Rottenberg, M.E., Guzman, C.A., Ljunggren, H.G., Malmberg, K.J., Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116 (2010), 3853–3864.
17. Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., Vitale, M., Moretta, L., Lopez, M., Moretta, A., Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198 (2003), 557–567.
18. Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C.D., Kaifu, T., Chabannon, C., Moretta, A., West, R., Xu, W., Vivier, E., Levin, S.D., The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206 (2009), 1495–1503.
19. Braud, V.M., Allan, D.S., O'Callaghan, C.A., Soderstrom, K., D'Andrea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H., Lanier, L.L., McMichael, A.J., HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998), 795–799.
20. Breitbach, C.J., Burke, J., Jonker, D., Stephenson, J., Haas, A.R., Chow, L.Q., Nieva, J., Hwang, T.H., Moon, A., Patt, R., Pelusio, A., Le Boeuf, F., Burns, J., Evgin, L., De Silva, N., Cvancic, S., Robertson, T., Je, J.E., Lee, Y.S., Parato, K., Diallo, J.S., Fenster, A., Daneshmand, M., Bell, J.C., Kirn, D.H., Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477 (2011), 99–102.
21. Briercheck, E.L., Trotta, R., Chen, L., Hartlage, A.S., Cole, J.P., Cole, T.D., Mao, C., Banerjee, P.P., Hsu, H.T., Mace, E.M., Ciarlariello, D., Mundy-Bosse, B.L., Garcia-Cao, I., Scoville, S.D., Yu, L., Pilarski, R., Carson, W.E. 3rd, Leone, G., Pandolfi, P.P., Yu, J., Orange, J.S., Caligiuri, M.A., PTEN is a negative regulator of NK cell cytolytic function. J. Immunol. 194 (2015), 1832–1840.
22. Carlsten, M., Norell, H., Bryceson, Y.T., Poschke, I., Schedvins, K., Ljunggren, H.G., Kiessling, R., Malmberg, K.J., Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183 (2009), 4921–4930.
23. Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., Linette, G.P., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
24. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002), 754–758.
25. Cerwenka, A., Bakker, A.B., McClanahan, T., Wagner, J., Wu, J., Phillips, J.H., Lanier, L.L., Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12 (2000), 721–727.
26. Cerwenka, A., Baron, J.L., Lanier, L.L., Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 11521–11526.
27. Cerwenka, A., Lanier, L.L., Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 1 (2001), 41–49.
28. Chalupny, N.J., Sutherland, C.L., Lawrence, W.A., Rein-Weston, A., Cosman, D., ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305 (2003), 129–135.
29. Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M.T., Town, L., Ritchie, D.S., Colonna, M., Andrews, D.M., Smyth, M.J., The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15 (2014), 431–438.
30. Chu, J., Deng, Y., Benson, D.M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., He, X., Devine, S.M., Zhang, X., Caligiuri, M.A., Hofmeister, C.C., Yu, J., CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28 (2014), 917–927.
31. Clayton, A., Mitchell, J.P., Court, J., Linnane, S., Mason, M.D., Tabi, Z., Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 180 (2008), 7249–7258.
32. Cooper, M.A., Elliott, J.M., Keyel, P.A., Yang, L., Carrero, J.A., Yokoyama, W.M., Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 1915–1919.
33. Cosman, D., Mullberg, J., Sutherland, C.L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., Chalupny, N.J., ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 (2001), 123–133.
34. Costello, R.T., Sivori, S., Marcenaro, E., Lafage-Pochitaloff, M., Mozziconacci, M.J., Reviron, D., Gastaut, J.A., Pende, D., Olive, D., Moretta, A., Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99 (2002), 3661–3667.
35. Coudert, J.D., Scarpellino, L., Gros, F., Vivier, E., Held, W., Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111 (2008), 3571–3578.
36. Coudert, J.D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., Held, W., Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106 (2005), 1711–1717.
37. Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M., Xenarios, I., Von Laer, D., Kalinke, U., Vivier, E., Jonjic, S., Oxenius, A., Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 40 (2014), 961–973.
38. Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M.R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., Paolini, S., Fruet, F., Isidori, A., Parisi, S., Bandini, G., Baccarani, M., Velardi, A., Lemoli, R.M., Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118 (2011), 3273–3279.
39. Dall'Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., Thibault, G., Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64 (2004), 4664–4669.
40. de Landazuri, M.O., Silva, A., Alvarez, J., Herberman, R.B., Evidence that natural cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by the same effector cell populations. J. Immunol. 123 (1979), 252–258.
41. Della Chiesa, M., Falco, M., Bertaina, A., Muccio, L., Alicata, C., Frassoni, F., Locatelli, F., Moretta, L., Moretta, A., Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C−/− umbilical cord blood. J. Immunol. 192 (2014), 1471–1479.
42. Deng, W., Gowen, B.G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T.L., Xiong, N., Raulet, D.H., Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348 (2015), 136–139.
43. Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., Raulet, D.H., Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1 (2000), 119–126.
44. Diefenbach, A., Jensen, E.R., Jamieson, A.M., Raulet, D.H., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001), 165–171.
45. Eagle, R.A., Traherne, J.A., Hair, J.R., Jafferji, I., Trowsdale, J., ULBP6/RAET1L is an additional human NKG2D ligand. Eur. J. Immunol. 39 (2009), 3207–3216.
46. Elliott, J.M., Wahle, J.A., Yokoyama, W.M., MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J. Exp. Med. 207 (2010), 2073–2079.
47. Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., Costello, R.T., Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109 (2007), 323–330.
48. Ferlazzo, G., Tsang, M.L., Moretta, L., Melioli, G., Steinman, R.M., Munz, C., Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195 (2002), 343–351.
49. Fiegler, N., Textor, S., Arnold, A., Rolle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens-Harig, M., Cerwenka, A., Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122 (2013), 684–693.
50. Foley, B., Cooley, S., Verneris, M.R., Curtsinger, J., Luo, X., Waller, E.K., Anasetti, C., Weisdorf, D., Miller, J.S., Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 189 (2012), 5082–5088.
51. Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
52. Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005), 1186–1190.
53. Gasser, S., Raulet, D.H., Activation and self-tolerance of natural killer cells. Immunol. Rev. 214 (2006), 130–142.
54. Gasteiger, G., Hemmers, S., Firth, M.A., Le Floc'h, A., Huse, M., Sun, J.C., Rudensky, A.Y., IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J. Exp. Med. 210 (2013), 1167–1178.
55. Geller, M.A., Miller, J.S., Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3 (2011), 1445–1459.
56. Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, B., Ballardini, B., Da Prada, G., Zambelli, A., Costa, A., Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10 (2004), 5650–5655.
57. Gerdes, C.A., Nicolini, V.G., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C.H., Bossenmaier, B., Mueller, H.J., Umana, P., GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 19 (2013), 1126–1138.
58. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., Nebuloni, M., van Rooijen, N., Mortarini, R., Beltrame, L., Marchini, S., Fuso Nerini, I., Sanfilippo, R., Casali, P.G., Pilotti, S., Galmarini, C.M., Anichini, A., Mantovani, A., D'Incalci, M., Allavena, P., Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23 (2013), 249–262.
59. Groh, V., Wu, J., Yee, C., Spies, T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002), 734–738.
60. Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Stanietsky-Kaynan, N., Coppenhagen-Glazer, S., Shussman, N., Almogy, G., Cuapio, A., Hofer, E., Mevorach, D., Tabib, A., Ortenberg, R., Markel, G., Miklic, K., Jonjic, S., Brennan, C.A., Garrett, W.S., Bachrach, G., Mandelboim, O., Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42 (2015), 344–355.
61. Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y.S., Kim, M.K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J.C., Rhee, B.G., Patt, R., Hwang, T.H., Kirn, D.H., Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19 (2013), 329–336.
62. Herberman, R.B., Ortaldo, J.R., Natural killer cells: their roles in defenses against disease. Science 214 (1981), 24–30.
63. Hilpert, J., Grosse-Hovest, L., Grunebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A., Salih, H.R., Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J. Immunol. 189 (2012), 1360–1371.
64. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbe, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
65. Horowitz, A., Strauss-Albee, D.M., Leipold, M., Kubo, J., Nemat-Gorgani, N., Dogan, O.C., Dekker, C.L., Mackey, S., Maecker, H., Swan, G.E., Davis, M.M., Norman, P.J., Guethlein, L.A., Desai, M., Parham, P., Blish, C.A., Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci. Transl. Med., 5, 2013, 208ra145.
66. Huntington, N.D., Puthalakath, H., Gunn, P., Naik, E., Michalak, E.M., Smyth, M.J., Tabarias, H., Degli-Esposti, M.A., Dewson, G., Willis, S.N., Motoyama, N., Huang, D.C., Nutt, S.L., Tarlinton, D.M., Strasser, A., Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8 (2007), 856–863.
67. Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356 (2000), 1795–1799.
68. Jie, H.B., Schuler, P.J., Lee, S.C., Srivastava, R.M., Argiris, A., Ferrone, S., Whiteside, T.L., Ferris, R.L., CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 75 (2015), 2200–2210.
69. Joncker, N.T., Shifrin, N., Delebecque, F., Raulet, D.H., Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J. Exp. Med. 207 (2010), 2065–2072.
70. Juelke, K., Killig, M., Luetke-Eversloh, M., Parente, E., Gruen, J., Morandi, B., Ferlazzo, G., Thiel, A., Schmitt-Knosalla, I., Romagnani, C., CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116 (2010), 1299–1307.
71. Kabat, J., Borrego, F., Brooks, A., Coligan, J.E., Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. J. Immunol. 169 (2002), 1948–1958.
72. Karo, J.M., Schatz, D.G., Sun, J.C., The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. Cell 159 (2014), 94–107.
73. Karre, K., Ljunggren, H.G., Piontek, G., Kiessling, R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986), 675–678.
74. Kelly, J.M., Darcy, P.K., Markby, J.L., Godfrey, D.I., Takeda, K., Yagita, H., Smyth, M.J., Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3 (2002), 83–90.
75. Kiessling, R., Klein, E., Pross, H., Wigzell, H., “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5 (1975), 117–121.
76. Kim, S., Poursine-Laurent, J., Truscott, S.M., Lybarger, L., Song, Y.J., Yang, L., French, A.R., Sunwoo, J.B., Lemieux, S., Hansen, T.H., Yokoyama, W.M., Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005), 709–713.
77. Kirkwood, J.M., Butterfield, L.H., Tarhini, A.A., Zarour, H., Kalinski, P., Ferrone, S., Immunotherapy of cancer in 2012. CA Cancer J. Clin. 62 (2012), 309–335.
78. Koene, H.R., Kleijer, M., Algra, J., Roos, D., von dem Borne, A.E., de Haas, M., Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90 (1997), 1109–1114.
79. Kohrt, H.E., Houot, R., Goldstein, M.J., Weiskopf, K., Alizadeh, A.A., Brody, J., Muller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M.P., Chen, L., Tedder, T.F., Levy, R., CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117 (2011), 2423–2432.
80. Kohrt, H.E., Houot, R., Weiskopf, K., Goldstein, M.J., Scheeren, F., Czerwinski, D., Colevas, A.D., Weng, W.K., Clarke, M.F., Carlson, R.W., Stockdale, F.E., Mollick, J.A., Chen, L., Levy, R., Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122 (2012), 1066–1075.
81. Kohrt, H.E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, E., Romagne, F., Levy, R., Blery, M., Andre, P., Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123 (2014), 678–686.
82. Koka, R., Burkett, P.R., Chien, M., Chai, S., Chan, F., Lodolce, J.P., Boone, D.L., Ma, A., Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J. Exp. Med. 197 (2003), 977–984.
83. Krebs, P., Barnes, M.J., Lampe, K., Whitley, K., Bahjat, K.S., Beutler, B., Janssen, E., Hoebe, K., NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 113 (2009), 6593–6602.
84. Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., Tadmor, A.D., Schoenberger, S.P., Huber, C., Tureci, O., Sahin, U., Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520 (2015), 692–696.
85. Krzewski, K., Strominger, J.L., The killer's kiss: the many functions of NK cell immunological synapses. Curr. Opin. Cell Biol. 20 (2008), 597–605.
86. Lanier, L.L., Ruitenberg, J.J., Phillips, J.H., Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J. Immunol. 141 (1988), 3478–3485.
87. Le Maux Chansac, B., Moretta, A., Vergnon, I., Opolon, P., Lecluse, Y., Grunenwald, D., Kubin, M., Soria, J.C., Chouaib, S., Mami-Chouaib, F., NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175 (2005), 5790–5798.
88. Lee, J., Zhang, T., Hwang, I., Kim, A., Nitschke, L., Kim, M., Scott, J.M., Kamimura, Y., Lanier, L.L., Kim, S., Epigenetic modification and antibody-dependent expansion of memory-like NK cells in Human cytomegalovirus-infected Individuals. Immunity 42 (2015), 431–442.
89. Lee, J.C., Lee, K.M., Kim, D.W., Heo, D.S., Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172 (2004), 7335–7340.
90. Leong, J.W., Chase, J.M., Romee, R., Schneider, S.E., Sullivan, R.P., Cooper, M.A., Fehniger, T.A., Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 20 (2014), 463–473.
91. Leong, J.W., Schneider, S.E., Sullivan, R.P., Parikh, B.A., Anthony, B.A., Singh, A., Jewell, B.A., Schappe, T., Wagner, J.A., Link, D.C., Yokoyama, W.M., Fehniger, T.A., PTEN regulates natural killer cell trafficking in vivo. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E700–E709.
92. Lopez-Verges, S., Milush, J.M., Schwartz, B.S., Pando, M.J., Jarjoura, J., York, V.A., Houchins, J.P., Miller, S., Kang, S.M., Norris, P.J., Nixon, D.F., Lanier, L.L., Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 14725–14732.
93. Lucas, M., Schachterle, W., Oberle, K., Aichele, P., Diefenbach, A., Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26 (2007), 503–517.
94. Luetke-Eversloh, M., Hammer, Q., Durek, P., Nordstrom, K., Gasparoni, G., Pink, M., Hamann, A., Walter, J., Chang, H.D., Dong, J., Romagnani, C., Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog., 10, 2014, e1004441.
95. Marechal, R., De Schutter, J., Nagy, N., Demetter, P., Lemmers, A., Deviere, J., Salmon, I., Tejpar, S., Van Laethem, J.L., Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer, 10, 2010, 340.
96. Martinet, L., Smyth, M.J., Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15 (2015), 243–254.
97. Matzinger, P., The danger model: a renewed sense of self. Science 296 (2002), 301–305.
98. Maus, M.V., Grupp, S.A., Porter, D.L., June, C.H., Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123 (2014), 2625–2635.
99. Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480 (2011), 480–489.
100. Messai, Y., Noman, M.Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., Ben Safta, T., Richon, C., Ferlicot, S., Donnadieu, E., Couve, S., Gardie, B., Orlanducci, F., Albiges, L., Thiery, J., Olive, D., Escudier, B., Chouaib, S., ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res. 74 (2014), 6820–6832.
101. Min-Oo, G., Bezman, N.A., Madera, S., Sun, J.C., Lanier, L.L., Proapoptotic Bim regulates antigen-specific NK cell contraction and the generation of the memory NK cell pool after cytomegalovirus infection. J. Exp. Med. 211 (2014), 1289–1296.
102. Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M.C., Moretta, A., Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18 (2006), 151–158.
103. Morse, M.A., Hobeika, A.C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H.K., Clay, T.M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112 (2008), 610–618.
104. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., Neri, T.M., Ardizzoni, A., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26 (2008), 1789–1796.
105. Nabekura, T., Kanaya, M., Shibuya, A., Fu, G., Gascoigne, N.R., Lanier, L.L., Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 40 (2014), 225–234.
106. Narni-Mancinelli, E., Jaeger, B.N., Bernat, C., Fenis, A., Kung, S., De Gassart, A., Mahmood, S., Gut, M., Heath, S.C., Estelle, J., Bertosio, E., Vely, F., Gastinel, L.N., Beutler, B., Malissen, B., Malissen, M., Gut, I.G., Vivier, E., Ugolini, S., Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 335 (2012), 344–348.
107. Ni, J., Miller, M., Stojanovic, A., Garbi, N., Cerwenka, A., Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209 (2012), 2351–2365.
108. O'Leary, J.G., Goodarzi, M., Drayton, D.L., von Andrian, U.H., T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7 (2006), 507–516.
109. Oppenheim, D.E., Roberts, S.J., Clarke, S.L., Filler, R., Lewis, J.M., Tigelaar, R.E., Girardi, M., Hayday, A.C., Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6 (2005), 928–937.
110. Pachynski, R.K., Zabel, B.A., Kohrt, H.E., Tejeda, N.M., Monnier, J., Swanson, C.D., Holzer, A.K., Gentles, A.J., Sperinde, G.V., Edalati, A., Hadeiba, H.A., Alizadeh, A.A., Butcher, E.C., The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 209 (2012), 1427–1435.
111. Pahl, J.H., Ruslan, S.E., Buddingh, E.P., Santos, S.J., Szuhai, K., Serra, M., Gelderblom, H., Hogendoorn, P.C., Egeler, R.M., Schilham, M.W., Lankester, A.C., Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin. Cancer Res. 18 (2012), 432–441.
112. Pahl, J.H., Ruslan, S.E., Kwappenberg, K.M., van Ostaijen-Ten Dam, M.M., van Tol, M.J., Lankester, A.C., Schilham, M.W., Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity. Cancer Immunol. Immunother. 62 (2013), 1235–1247.
113. Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A.M., Langdon, W.Y., Ikeda, F., Fededa, J.P., Cronin, S.J., Nitsch, R., Schultz-Fademrecht, C., Eickhoff, J., Menninger, S., Unger, A., Torka, R., Gruber, T., Hinterleitner, R., Baier, G., Wolf, D., Ullrich, A., Klebl, B.M., Penninger, J.M., The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507 (2014), 508–512.
114. Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., Liu, Y., Tang, J., Wang, S., Fu, Y.X., The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18 (2010), 160–170.
115. Parkhurst, M.R., Riley, J.P., Dudley, M.E., Rosenberg, S.A., Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17 (2011), 6287–6297.
116. Parrish, C., Scott, G.B., Migneco, G., Scott, K.J., Steele, L.P., Ilett, E., West, E.J., Hall, K., Selby, P.J., Buchanan, D., Varghese, A., Cragg, M.S., Coffey, M., Hillmen, P., Melcher, A.A., Errington-Mais, F., Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, 2015, 10.1038/leu.2015.88 (advance online publication 24 April 2015).
117. Paust, S., Gill, H.S., Wang, B.Z., Flynn, M.P., Moseman, E.A., Senman, B., Szczepanik, M., Telenti, A., Askenase, P.W., Compans, R.W., von Andrian, U.H., Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11 (2010), 1127–1135.
118. Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., Solari, N., Gualco, M., Queirolo, P., Moretta, L., Mingari, M.C., Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72 (2012), 1407–1415.
119. Prestwich, R.J., Errington, F., Steele, L.P., Ilett, E.J., Morgan, R.S., Harrington, K.J., Pandha, H.S., Selby, P.J., Vile, R.G., Melcher, A.A., Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J. Immunol. 183 (2009), 4312–4321.
120. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., Snyder, L.A., Pollard, J.W., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 (2011), 222–225.
121. Reiners, K.S., Topolar, D., Henke, A., Simhadri, V.R., Kessler, J., Sauer, M., Bessler, M., Hansen, H.P., Tawadros, S., Herling, M., Kronke, M., Hallek, M., Pogge von Strandmann, E., Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121 (2013), 3658–3665.
122. Rolle, A., Pollmann, J., Ewen, E.M., Le, V.T., Halenius, A., Hengel, H., Cerwenka, A., IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J. Clin. Invest. 124 (2014), 5305–5316.
123. Romee, R., Schneider, S.E., Leong, J.W., Chase, J.M., Keppel, C.R., Sullivan, R.P., Cooper, M.A., Fehniger, T.A., Cytokine activation induces human memory-like NK cells. Blood 120 (2012), 4751–4760.
124. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
125. Rubnitz, J.E., Inaba, H., Ribeiro, R.C., Pounds, S., Rooney, B., Bell, T., Pui, C.H., Leung, W., NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28 (2010), 955–959.
126. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F., Velardi, A., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002), 2097–2100.
127. Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., Chaigneau, L., Le Brun-Ly, V., Dubreuil, P., Cremer, I., Caignard, A., Poirier-Colame, V., Chaba, K., Flament, C., Halama, N., Jager, D., Eggermont, A., Bonvalot, S., Commo, F., Terrier, P., Opolon, P., Emile, J.F., Coindre, J.M., Kroemer, G., Chaput, N., Le Cesne, A., Blay, J.Y., Zitvogel, L., Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73 (2013), 3499–3510.
128. Rydyznski, C., Daniels, K.A., Karmele, E.P., Brooks, T.R., Mahl, S.E., Moran, M.T., Li, C., Sutiwisesak, R., Welsh, R.M., Waggoner, S.N., Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat. Commun., 6, 2015, 6375.
129. Salih, H.R., Rammensee, H.G., Steinle, A., Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169 (2002), 4098–4102.
130. Schlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E.P., Textor, S., Cerwenka, A., Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res. 74 (2014), 3429–3440.
131. Schlums, H., Cichocki, F., Tesi, B., Theorell, J., Beziat, V., Holmes, T.D., Han, H., Chiang, S.C., Foley, B., Mattsson, K., Larsson, S., Schaffer, M., Malmberg, K.J., Ljunggren, H.G., Miller, J.S., Bryceson, Y.T., Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42 (2015), 443–456.
132. Schonfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bonig, H., Kohl, U., Kloess, S., Kohler, S., Holtgreve-Grez, H., Jauch, A., Schmidt, M., Schubert, R., Kuhlcke, K., Seifried, E., Klingemann, H.G., Rieger, M.A., Tonn, T., Grez, M., Wels, W.S., Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23 (2015), 330–338.
133. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
134. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
135. Schuster, I.S., Wikstrom, M.E., Brizard, G., Coudert, J.D., Estcourt, M.J., Manzur, M., O'Reilly, L.A., Smyth, M.J., Trapani, J.A., Hill, G.R., Andoniou, C.E., Degli-Esposti, M.A., TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. Immunity 41 (2014), 646–656.
136. Smyth, M.J., Cretney, E., Kelly, J.M., Westwood, J.A., Street, S.E., Yagita, H., Takeda, K., van Dommelen, S.L., Degli-Esposti, M.A., Hayakawa, Y., Activation of NK cell cytotoxicity. Mol. Immunol. 42 (2005), 501–510.
137. Smyth, M.J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W.M., Hayakawa, Y., NKG2D function protects the host from tumor initiation. J. Exp. Med. 202 (2005), 583–588.
138. Soderquest, K., Walzer, T., Zafirova, B., Klavinskis, L.S., Polic, B., Vivier, E., Lord, G.M., Martin-Fontecha, A., Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J. Immunol. 186 (2011), 3304–3308.
139. Srivastava, R.M., Lee, S.C., Andrade Filho, P.A., Lord, C.A., Jie, H.B., Davidson, H.C., Lopez-Albaitero, A., Gibson, S.P., Gooding, W.E., Ferrone, S., Ferris, R.L., Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 19 (2013), 1858–1872.
140. Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., Stern-Ginossar, N., Tsukerman, P., Jonjic, S., Mandelboim, O., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 17858–17863.
141. Stojanovic, A., Cerwenka, A., Natural killer cells and solid tumors. J. Innate Immun. 3 (2011), 355–364.
142. Sun, J.C., Beilke, J.N., Lanier, L.L., Adaptive immune features of natural killer cells. Nature 457 (2009), 557–561.
143. Sun, J.C., Madera, S., Bezman, N.A., Beilke, J.N., Kaplan, M.H., Lanier, L.L., Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J. Exp. Med. 209 (2012), 947–954.
144. Sun, J.C., Ugolini, S., Vivier, E., Immunological memory within the innate immune system. EMBO J. 33 (2014), 1295–1303.
145. Tarek, N., Le Luduec, J.B., Gallagher, M.M., Zheng, J., Venstrom, J.M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.K., Hsu, K.C., Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122 (2012), 3260–3270.
146. Thielens, A., Vivier, E., Romagne, F., NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24 (2012), 239–245.
147. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
148. Tu, T.C., Brown, N.K., Kim, T.J., Wroblewska, J., Yang, X., Guo, X., Lee, S.H., Kumar, V., Lee, K.M., Fu, Y.X., CD160 is essential for NK-mediated IFN-gamma production. J. Exp. Med. 212 (2015), 415–429.
149. Ullrich, E., Koch, J., Cerwenka, A., Steinle, A., New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology, 2, 2013, e26097.
150. Vance, B.A., Huizinga, T.W., Wardwell, K., Guyre, P.M., Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J. Immunol. 151 (1993), 6429–6439.
151. Veeramani, S., Wang, S.Y., Dahle, C., Blackwell, S., Jacobus, L., Knutson, T., Button, A., Link, B.K., Weiner, G.J., Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118 (2011), 3347–3349.
152. Viaud, S., Daillere, R., Boneca, I.G., Lepage, P., Pittet, M.J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., Zitvogel, L., Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res. 74 (2014), 4217–4221.
153. Vitale, M., Cantoni, C., Pietra, G., Mingari, M.C., Moretta, L., Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44 (2014), 1582–1592.
154. Vivier, E., Morin, P., O'Brien, C., Druker, B., Schlossman, S.F., Anderson, P., Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J. Immunol. 146 (1991), 206–210.
155. Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., Ugolini, S., Innate or adaptive immunity? The example of natural killer cells. Science 331 (2011), 44–49.
156. Vivier, E., Tomasello, E., Baratin, M., Walzer, T., Ugolini, S., Functions of natural killer cells. Nat. Immunol. 9 (2008), 503–510.
157. Waggoner, S.N., Cornberg, M., Selin, L.K., Welsh, R.M., Natural killer cells act as rheostats modulating antiviral T cells. Nature 481 (2012), 394–398.
158. Waggoner, S.N., Daniels, K.A., Welsh, R.M., Therapeutic depletion of natural killer cells controls persistent infection. J. Virol. 88 (2014), 1953–1960.
159. Wendel, M., Galani, I.E., Suri-Payer, E., Cerwenka, A., Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68 (2008), 8437–8445.
160. Weng, W.K., Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003), 3940–3947.
161. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., Burke, M.M., Caldwell, A., Kronenberg, S.A., Agunwamba, B.U., Zhang, X., Lowy, I., Inzunza, H.D., Feely, W., Horak, C.E., Hong, Q., Korman, A.J., Wigginton, J.M., Gupta, A., Sznol, M., Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
162. Wu, C., Li, B., Lu, R., Koelle, S.J., Yang, Y., Jares, A., Krouse, A.E., Metzger, M., Liang, F., Lore, K., Wu, C.O., Donahue, R.E., Chen, I.S., Weissman, I., Dunbar, C.E., Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells. Cell Stem Cell 14 (2014), 486–499.
163. Xu, H.C., Grusdat, M., Pandyra, A.A., Polz, R., Huang, J., Sharma, P., Deenen, R., Kohrer, K., Rahbar, R., Diefenbach, A., Gibbert, K., Lohning, M., Hocker, L., Waibler, Z., Haussinger, D., Mak, T.W., Ohashi, P.S., Lang, K.S., Lang, P.A., Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 40 (2014), 949–960.
164. Yang, X., Zhang, X., Mortenson, E.D., Radkevich-Brown, O., Wang, Y., Fu, Y.X., Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol. Ther. 21 (2013), 91–100.
165. Zamarin, D., Holmgaard, R.B., Subudhi, S.K., Park, J.S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J.D., Allison, J.P., Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med., 6(226), 2014, ra232.
166. Zhang, W., Gordon, M., Schultheis, A.M., Yang, D.Y., Nagashima, F., Azuma, M., Chang, H.M., Borucka, E., Lurje, G., Sherrod, A.E., Iqbal, S., Groshen, S., Lenz, H.J., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25 (2007), 3712–3718.